跳至主要内容
临床试验/NCT00645671
NCT00645671已完成3 期

A Randomized Multicenter, Double-Masked, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate Ophthalmic Ointment, 0.5% Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery

Bausch & Lomb Incorporated1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2008年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
400
试验地点
1
主要终点
Grade 0 for Pain

研究概览

简要总结

To evaluate the clinical safety and efficacy of Loteprednol Etabonate Ophthalmic Ointment, 0.5% vs. vehicle for the treatment of inflammation following cataract surgery

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects who are candidate for routine, uncomplicated cataract surgery
  • Subjects who, in the Investigator's opinion, have potential postoperative pinholed Snellen visual acuity (VA) of at least 20/200 in the study eye.

排除标准

  • Subjects who will require concurrent ocular therapy with NSAIDs, mast cell stabilizers, antihistamines, decongestants, or immunosuppressants (e.g., Restasis), or with ocular or systemic corticosteroids
  • Subjects who have known hypersensitivity or contraindication to the study drug(s) or their components
  • Subjects who are monocular or have pinholed Snellen VA 20/200 or worse in the non-study eye
  • Subjects who have had ocular surgery (including laser surgery) in the study eye within 3 months or in the fellow eye within 2 weeks prior to the Screening Visit

研究组 & 干预措施

Loteprednol Etabonate

Experimental

Loteprednol etabonate 0.5% ophthalmic ointment

干预措施: 0.5% Loteprednol Etabonate Ophthalmic Ointment (Drug)

Vehicle

Placebo Comparator

Vehicle of loteprednol etabonate ointment

干预措施: Vehicle of Loteprednol Etabonate Ophthalmic Ointment (Drug)

结局指标

主要结局

Grade 0 for Pain

时间窗: Postoperative Day 8 (Visit 5)

Pain: A positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching. Grade 0 = None; 1=Minimal; 2=Mild; 3=Moderate; 4=Moderately Severe; 5=Severe

Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0.

时间窗: Postoperative Day 8 (Visit 5)

A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= \>30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.

次要结局

  • Subjects With Complete Resolution of Anterior Chamber Cells and Flare. At Each Follow-up Visit.(At each follow-up visit through day18 (Visit 7))
  • Change From Baseline to Each Follow-up Visit in Anterior Chamber Cells and Flare(Baseline and each follow-up visit through day18 (Visit 7))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验